CODEN [USA]: IAJPBB ISSN : 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES
SJIF Impact Factor: 7.187
https://doi.org/10.5281/zenodo.22852858

Available online at: http://www.iajps.com Review Article

COMPARATIVE STUDY OF INDIA'S SCHEDULE M VERSUS WHO-GMP GUIDELINES FOR PHARMACEUTICAL MANUFACTURING

Ishwarya Gitta*[1], P. Srikanth[2]

[1]Department Of Regulatory Affairs , Vaagdevi Pharmacy College,Bollikunta, Warangal, Telangana, India, 506005.

[2]Associate Professor, Vaagdevi Pharmacy College, Bollikunta,Warangal, Telangana, India, 506005

Abstract:

The pharmaceutical industry operates under stringent regulatory frameworks to ensure drug quality, safety, and efficacy. In India, Schedule M of the Drugs and Cosmetics Act provides mandatory requirements for pharmaceutical manufacturing, covering areas such as facilities, equipment, personnel, documentation, and quality control. Globally, the World Health Organization's Good Manufacturing Practices (WHO-GMP) guidelines offer comprehensive standards emphasizing risk-based approaches, process validation, data integrity, and continuous quality improvement. This study presents a comparative analysis of India's Schedule M and WHO-GMP guidelines, identifying similarities, differences, and areas of convergence in facility design, production processes, quality assurance, documentation, and personnel training. The analysis highlights regulatory gaps, challenges faced by Indian manufacturers in achieving international compliance, and opportunities for harmonization to facilitate global market access. The findings underscore the importance of aligning domestic regulations with international standards to enhance product quality, ensure patient safety, and strengthen India's position in the global pharmaceutical industry.

Keywords: *Schedule M, WHO-GMP, pharmaceutical manufacturing, quality assurance, regulatory compliance, process validation, data integrity, international harmonization*

Corresponding author:

Ishwarya Gitta,

Department of Regulatory Affairs, Vaagdevi Pharmacy College, Warangal, Telangana

Mobile:

Email Id-

QR CODE

Please cite this article in press ***Ishwarya Gitta*** *et al.,* ***Comparative Study Of India's Schedule M Versus Who-Gmp Guidelines For Pharmaceutical Manufacturing.,****. Indo Am. J. P. Sci, 2026; 13(09).*

INTRODUCTION:

Background of Pharmaceutical Manufacturing

The pharmaceutical industry occupies a pivotal role in global healthcare systems, serving as the backbone for disease prevention, treatment, and management. It is not merely an economic sector but a critical public health resource, tasked with producing safe, effective, and high-quality medicines for diverse populations. The industry encompasses a broad spectrum of activities, including research and development (R&D), active pharmaceutical ingredient (API) synthesis, drug formulation, quality control, packaging, and distribution. Each stage of manufacturing is intertwined with regulatory oversight, scientific innovation, and ethical responsibility.

1.1 Importance and Scope

The demand for pharmaceuticals has risen dramatically over the past few decades due to multiple factors. Rapid population growth, increased life expectancy, rising prevalence of chronic diseases, and the emergence of new infectious diseases have amplified the global need for medicines. Simultaneously, patient awareness and expectations regarding drug safety and efficacy have increased. As a result, manufacturers are compelled to adopt sophisticated production technologies and adhere to stringent quality management systems.

Pharmaceutical manufacturing is inherently complex, involving chemical, biological, and mechanical processes that must be carefully optimized to ensure product consistency. For example, API synthesis requires precise control over chemical reactions to achieve the desired purity and potency, while formulation development ensures that the drug can be delivered safely and effectively to patients. In addition, packaging must maintain the integrity of the product during storage, transport, and administration.

1.2 Historical Context

The evolution of pharmaceutical manufacturing has been profoundly shaped by historical events that exposed the consequences of inadequate quality control. The thalidomide tragedy of the late 1950s and early 1960s, in which thousands of infants were born with congenital deformities due to a sedative drug, became a turning point in drug regulation. Such incidents underscored the critical need for robust manufacturing standards, systematic clinical evaluation, and post-marketing surveillance.

In response, countries began to develop regulatory frameworks and guidelines to enforce drug safety, culminating in the establishment of Good Manufacturing Practices (GMP). GMP provides a structured approach to manufacturing, emphasizing process control, documentation, personnel training, facility design, equipment maintenance, and quality testing. It ensures that each batch of a drug meets defined specifications, thereby reducing the risk of contamination, adulteration, or variability in efficacy.

1.3 Regulatory and Ethical Dimensions

Pharmaceutical manufacturing extends beyond technical execution to encompass regulatory compliance and ethical accountability. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and India's Central Drugs Standard Control Organization (CDSCO), set stringent standards for drug production, inspection, and certification. Non-compliance with these standards can result in severe consequences, including product recalls, legal penalties, and reputational damage.

Ethically, manufacturers have a responsibility to protect patient health. Defective or substandard medicines can cause severe adverse events, compromise treatment outcomes, and erode public confidence in healthcare systems. As such, pharmaceutical companies must integrate quality assurance into every aspect of their operations, from raw material procurement to final product release.

1.4 Globalization and Harmonization

In the contemporary era, pharmaceutical manufacturing operates in a highly globalized environment. Active ingredients, excipients, and finished products often cross multiple international borders. This global trade necessitates harmonization of manufacturing standards to ensure that medicines meet universally accepted quality criteria. Organizations such as the World Health Organization (WHO), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and regional regulatory bodies provide guidelines that facilitate international regulatory convergence.

Harmonization not only enhances the quality and safety of medicines worldwide but also supports efficient regulatory review, reduces duplication of inspections, and enables access to international markets. For manufacturers, compliance with

global standards is both a strategic and ethical imperative, ensuring patient safety while maintaining competitiveness in the international pharmaceutical landscape.

1.5 Technological Advancements in Manufacturing

Modern pharmaceutical manufacturing has evolved with advancements in technology and automation. Process analytical technology (PAT), continuous manufacturing, high-throughput screening, and computer-aided formulation design are now integral to ensuring product quality and consistency. These innovations allow for real-time monitoring of critical parameters, rapid identification of deviations, and improved efficiency.

Furthermore, digital tools such as electronic batch records (EBRs), laboratory information management systems (LIMS), and artificial intelligence (AI)-driven predictive models have enhanced data integrity, traceability, and decision-making in manufacturing operations. Such technologies are increasingly essential in meeting both regulatory expectations and patient demands for high-quality medicines.

2. Regulatory Framework in India

India's pharmaceutical industry has emerged as a global leader, recognized for its high-volume generic drug production and growing contribution to innovative drug development. The country ranks among the top producers of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs), supplying medicines both domestically and to over 200 international markets. This dual role—serving domestic healthcare needs while meeting global demand—necessitates a robust regulatory framework to ensure safety, efficacy, and quality of pharmaceuticals.

2.1 Legal Foundations: Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act (DCA) of 1940 is the cornerstone of pharmaceutical regulation in India. Enacted to regulate the import, manufacture, distribution, and sale of drugs and cosmetics, the Act has undergone multiple amendments to address emerging challenges, evolving scientific standards, and international regulatory expectations. It provides a comprehensive framework to safeguard public health by ensuring that medicines meet predefined quality, safety, and efficacy standards before reaching consumers.

Within the Act, various schedules provide detailed technical requirements for specific aspects of drug regulation. Among these, Schedule M is particularly critical as it governs the Good Manufacturing Practices (GMP) and infrastructure standards necessary for pharmaceutical manufacturing.

2.2 Schedule M: Scope and Applicability

Schedule M lays down legally binding requirements for the manufacture of pharmaceuticals in India. Its provisions cover the entire spectrum of manufacturing, including raw material handling, production processes, packaging, quality control, and storage.

Key aspects of Schedule M include:

- Premises and Facility Design: Specifies layout, ventilation, air handling, lighting, sanitation, and pest control to minimize contamination risks. Facilities must be designed to separate different production areas and prevent cross-contamination.
- Equipment Requirements: Outlines standards for machinery, instruments, and cleaning procedures. Equipment must be properly installed, maintained, and calibrated to ensure consistent performance.
- Personnel Standards: Defines qualifications, training requirements, hygiene standards, and responsibilities for production and quality control staff. Competent personnel are essential for maintaining GMP compliance.
- Documentation and Record-Keeping: Emphasizes meticulous record maintenance for production batches, quality control testing, deviations, and corrective actions. Proper documentation ensures traceability and accountability.
- Production Practices: Provides guidelines for process validation, in-process checks, and adherence to standardized operating procedures (SOPs) to maintain product consistency.
- Quality Control: Mandates systematic testing of raw materials, in-process samples, and finished products to confirm identity, potency, purity, and stability.
- Storage and Distribution: Addresses conditions for warehousing, temperature control, labeling, and transportation to preserve product integrity until it reaches consumers.

The applicability of Schedule M extends to all manufacturers producing drugs for sale in India, including both domestic formulations and imported APIs that are processed or repackaged locally. Non-compliance can lead to suspension of licenses, product recalls, or legal penalties, highlighting the regulatory significance of adhering to these standards.

2.3 Role of CDSCO

The Central Drugs Standard Control Organization (CDSCO) serves as the national regulatory authority for pharmaceuticals in India. Operating under the Ministry of Health and Family Welfare, CDSCO is tasked with implementing the provisions of the Drugs and Cosmetics Act, including the enforcement of Schedule M. Its responsibilities include:

- Licensing and Registration: Granting manufacturing licenses, approvals for new drugs, and registration of pharmaceutical products.
- Inspection and Auditing: Conducting routine and for-cause inspections of manufacturing facilities to verify compliance with Schedule M and other relevant regulations.
- Quality Assurance Oversight: Ensuring that production, storage, and distribution practices maintain the safety, efficacy, and quality of medicines.
- Policy Development and Guidance: Updating guidelines in alignment with global GMP standards and providing clarity to manufacturers on regulatory expectations.

Schedule M compliance is mandatory for domestic manufacturers and forms the backbone of India's pharmaceutical quality framework. It not only safeguards public health but also supports the credibility of Indian pharmaceutical exports by demonstrating adherence to internationally recognized manufacturing practices.

2.4 Harmonization with Global Standards

In recent years, India has actively aligned its regulations with global standards such as the World Health Organization (WHO) GMP and International Council for Harmonisation (ICH) guidelines. Harmonization facilitates export opportunities, streamlines regulatory inspections by foreign agencies, and strengthens confidence in Indian pharmaceuticals on the international stage. CDSCO plays a key role in driving this alignment, conducting training programs, and issuing updated guidance documents that integrate global best practices into domestic manufacturing regulations.

2.5 Challenges and Future Directions

Despite its robust regulatory framework, India faces challenges in consistent GMP compliance, particularly among small and medium-sized enterprises (SMEs). Issues such as outdated facilities, insufficient training, and gaps in documentation can hinder adherence to Schedule M requirements. Addressing these challenges requires continuous capacity building, investment in modern infrastructure, adoption of digital quality management systems, and proactive engagement with CDSCO for regulatory guidance.

The regulatory framework, anchored by Schedule M and enforced by CDSCO, remains central to India's commitment to producing safe, high-quality medicines for domestic and international markets. Continuous updates, harmonization with global standards, and technological modernization are key to maintaining India's leadership in pharmaceutical manufacturing.

3. WHO-GMP Guidelines

The World Health Organization (WHO) provides a globally recognized framework for Good Manufacturing Practices (GMP) in the pharmaceutical sector. WHO-GMP guidelines aim to ensure that medicinal products are consistently manufactured to meet quality, safety, and efficacy standards suitable for their intended use. These guidelines are particularly influential in countries lacking detailed national GMP regulations, serving both as a regulatory benchmark and a tool for capacity building in the pharmaceutical industry.

Unlike prescriptive regulatory frameworks such as India's Schedule M, WHO-GMP adopts a risk-based, process-oriented approach, focusing on the identification, control, and continuous mitigation of risks to product quality. This approach aligns with modern quality management philosophies and international standards for pharmaceutical production.

3.1 Key Principles of WHO-GMP

WHO-GMP guidelines are structured around several fundamental principles that collectively ensure product quality and patient safety:

1. **Quality Assurance (QA):** QA encompasses all organizational activities and systems designed to ensure that medicines meet established quality standards. It includes oversight of

personnel, facilities, equipment, processes, and documentation. QA emphasizes proactive measures to prevent errors rather than relying solely on end-product testing.

2. **Quality Control (QC):** QC focuses on scientific evaluation of raw materials, in-process materials, and finished products through systematic testing and analysis. QC ensures that each batch meets predetermined specifications for identity, potency, purity, and safety. Laboratories conducting QC must adhere to strict validation, calibration, and documentation practices.
3. **Risk-Based Approach:** WHO-GMP encourages manufacturers to identify, evaluate, and mitigate risks that could compromise product quality. Risk assessment may include critical process parameters, contamination control, supply chain vulnerabilities, and potential human errors. By prioritizing critical control points, manufacturers can prevent defects and ensure consistent product quality.
4. **Process Validation:** Validation is a central tenet of WHO-GMP, requiring that all critical manufacturing processes are proven to produce consistent results. This includes process qualification, equipment validation, cleaning validation, and continuous monitoring of key performance indicators. Validated processes reduce variability and enhance confidence in product integrity.
5. **Documentation and Data Integrity (ALCOA+):** Accurate, transparent, and reliable documentation is critical for GMP compliance. WHO-GMP emphasizes the ALCOA+ principles:
    - Attributable: Records clearly identify the person performing the task.
    - Legible: Information is readable and understandable.
    - Contemporaneous: Data is recorded at the time the activity occurs.
    - Original: Original records are preserved.
    - Accurate: Data reflects the true results.
    - Complete, Consistent, Enduring, and Available: Ensures comprehensive, standardized, durable, and retrievable documentation.
6. **Continuous Improvement:** WHO-GMP encourages manufacturers to regularly review and optimize processes, systems, and practices. Corrective and preventive actions (CAPA) are implemented to address deviations, improve efficiency, and enhance product quality. Continuous improvement fosters innovation, regulatory compliance, and customer satisfaction.

3.2 Global Relevance of WHO-GMP

WHO-GMP guidelines are widely adopted in both developed and developing countries, often serving as a reference for national regulatory authorities. Compliance with WHO-GMP is a prerequisite for international trade and export of pharmaceuticals, particularly to markets requiring stringent quality standards such as the European Union, the United States, and other WHO member states.

Manufacturers aiming to enter global markets must demonstrate alignment with WHO-GMP, which includes:

- Auditable documentation for all production and QC activities.
- Proper facility and equipment design to prevent contamination and cross-contamination.
- Training programs for personnel to uphold GMP practices.
- Robust systems for risk management, process validation, and quality assurance.

3.3 Integration with National Regulations

Many countries, including India, align their domestic regulations with WHO-GMP to ensure international compatibility. While Schedule M in India is largely prescriptive, focusing on defined standards for premises, equipment, and processes, WHO-GMP provides a flexible, risk-based framework. The integration of WHO-GMP principles into national regulations enhances quality assurance, facilitates inspections by international regulatory agencies, and strengthens confidence in the pharmaceutical supply chain.

3.4 Technological and Operational Considerations

Adherence to WHO-GMP has been further strengthened by technological advancements in pharmaceutical manufacturing. Automated systems, process analytical technology (PAT), electronic batch records (EBR), and laboratory information management systems (LIMS) improve process control, data integrity, and traceability. These technologies support WHO-GMP's

emphasis on risk management, documentation, and continuous improvement.

3.5 Benefits of WHO-GMP Compliance

- Ensures consistent production of safe and effective medicines.
- Reduces the risk of contamination, adulteration, and batch variability.
- Enhances regulatory compliance and inspection readiness.
- Facilitates access to global pharmaceutical markets.
- Promotes a culture of quality, accountability, and continuous improvement within manufacturing organizations.

In conclusion, WHO-GMP guidelines provide a comprehensive, globally recognized standard that complements national regulatory frameworks. By emphasizing quality systems, risk management, process validation, and continuous improvement, WHO-GMP ensures that pharmaceutical manufacturers can consistently deliver safe, effective, and high-quality medicines to patients worldwide.

4. Rationale for Comparison

The Indian pharmaceutical industry plays a pivotal role in both domestic healthcare and the global pharmaceutical supply chain. With India being one of the largest producers of generic medicines and active pharmaceutical ingredients (APIs), its products reach over 200 countries worldwide. This global presence underscores the importance of maintaining manufacturing standards that are consistent, reliable, and internationally recognized. In this context, comparing India's Schedule M regulations with the WHO-GMP guidelines is not merely an academic exercise but a strategic necessity.

4.1 Ensuring Compliance with International Quality Standards

One of the primary motivations for a comparative analysis is to assess how Indian manufacturing regulations align with internationally accepted standards. While Schedule M provides a detailed, prescriptive framework for facilities, equipment, and processes, WHO-GMP offers a risk-based, process-oriented approach. Identifying similarities and differences helps manufacturers:

- Understand areas where Schedule M meets, exceeds, or falls short of global expectations.
- Implement corrective measures to ensure consistent product quality, safety, and efficacy.
- Adopt best practices that reduce the likelihood of regulatory non-compliance during inspections by foreign authorities.

DISCUSSION

The comparative analysis of India's Schedule M and the World Health Organization's Good Manufacturing Practices (WHO-GMP) guidelines highlights several important themes relevant to regulatory science, industry practice, and global pharmaceutical quality assurance.

1. Regulatory Philosophies: Prescriptive vs. Risk-Based

One of the most fundamental distinctions between India's Schedule M and the WHO Good Manufacturing Practices (WHO-GMP) lies in their underlying regulatory philosophy.

1.1 Prescriptive Approach of Schedule M

Schedule M, part of India's Drugs and Cosmetics Act, 1940, has historically been prescriptive in nature. It provides detailed, legally binding requirements for pharmaceutical manufacturing, including:

- Infrastructure and Facility Design: Specifications for production area layouts, segregation of manufacturing zones, sanitation, lighting, ventilation, and air handling systems.
- Process Controls: Detailed requirements for equipment installation, maintenance, and calibration.
- Personnel Standards: Prescribed qualifications, training requirements, and hygiene protocols.
- Documentation: Requirements for batch records, quality control logs, and standard operating procedures (SOPs).

This prescriptive framework offers several advantages:

- Clarity and Consistency: Manufacturers have a well-defined checklist for compliance, reducing ambiguity.
- Baseline Safety Assurance: Minimum standards for equipment, facilities, and personnel ensure a foundational level of product safety and quality.
- Ease of Enforcement: Regulators can inspect facilities and processes against

clear, predefined requirements, facilitating enforcement and audit processes.

However, the prescriptive nature also has limitations:

- Limited Flexibility: Manufacturers may find it challenging to adopt innovative technologies, alternative processes, or modern production methods without explicit regulatory updates.
- Static Compliance: Focus on checklists may encourage meeting minimum requirements rather than fostering a culture of continuous improvement.
- Reactive Risk Management: Risk identification and mitigation are often performed post-facto, rather than proactively integrating risk management throughout the manufacturing lifecycle.

1.2 Risk-Based and Outcome-Oriented WHO-GMP

In contrast, WHO-GMP adopts a risk-based, outcome-oriented framework that emphasizes achieving consistent product quality rather than prescribing the exact methods to do so. Key features include:

- Quality Risk Management (QRM): Manufacturers are expected to identify, assess, and mitigate risks at every critical stage of production—from raw material procurement to finished product release.
- Process Validation: Focus on demonstrating that manufacturing processes consistently produce products meeting predetermined quality specifications.
- Flexibility in Technology and Methods: WHO-GMP allows the use of innovative approaches, such as continuous manufacturing, automation, or Process Analytical Technology (PAT), provided that the chosen methods ensure equivalent or superior assurance of quality.
- Outcome-Focused Compliance: Compliance is measured by the effectiveness of systems and processes in ensuring product quality, rather than adherence to rigid specifications.

1.3 Practical Implications of the Philosophical Differences

1. Risk Management:
   - Under WHO-GMP, risk assessment tools such as Failure Mode and Effects Analysis (FMEA), hazard analysis, and preventive controls are formally integrated into quality systems.
   - Schedule M compliance often relies on static checklists, limiting proactive risk mitigation, particularly in dynamic manufacturing environments or in response to emerging contamination or process challenges.
2. **Innovation and Process Optimization:**
   - WHO-GMP's flexible framework encourages the adoption of advanced manufacturing technologies and continuous process improvement.
   - Schedule M may constrain such innovation unless the regulatory framework is explicitly updated, potentially slowing modernization in facilities, especially for small- and medium-scale manufacturers.
3. **Regulatory and Inspection Paradigms:**
   - WHO-GMP audits focus on risk-based quality outcomes and the effectiveness of QA systems, rather than strict adherence to prescriptive layouts or equipment specifications.
   - Schedule M inspections typically verify compliance with defined infrastructural and procedural standards, which may not fully assess the adequacy of risk management or process performance.

1.4 Alignment with Modern Quality Paradigms

WHO-GMP's risk-based philosophy aligns closely with modern quality paradigms such as:

- Quality by Design (QbD): Designing processes with predefined quality objectives and using risk assessment to control variability.
- Continuous Improvement: Encouraging ongoing evaluation and enhancement of processes, reducing deviations, and preventing quality failures.
- Global Market Compliance: Facilitating export to highly regulated markets (FDA, EMA, PMDA) where risk-based GMP compliance is expected.

Schedule M, while essential for ensuring minimum standards, provides a strong foundational framework but may require updates and harmonization to fully incorporate risk-based thinking, process validation, and outcome-oriented quality systems.

1.5 Case Illustrations

- Small-scale manufacturers relying solely on Schedule M may inadvertently overlook process variability or emerging

contamination risks, as highlighted in incidents like the toxic cough syrup case.
- Large-scale manufacturers integrating WHO-GMP principles have successfully implemented validated processes, electronic batch records, and risk-based QA systems, enabling both domestic and international compliance.

2. Documentation, Data Integrity, and Traceability

Documentation is a cornerstone of Good Manufacturing Practices (GMP), serving as the primary evidence that pharmaceutical products are consistently manufactured to meet quality, safety, and efficacy standards. Both India's Schedule M and WHO-GMP emphasize the importance of maintaining accurate records; however, WHO-GMP delineates documentation requirements with far greater depth, especially in the context of modern digital manufacturing and data integrity.

2.1 Schedule M Documentation

Schedule M mandates comprehensive record-keeping covering all critical aspects of manufacturing, including:

- Batch Manufacturing Records (BMRs): Detailed instructions and records for every batch of product, including raw materials, quantities, equipment used, and in-process checks.
- Quality Control (QC) Logs: Records of raw material testing, in-process sampling, and finished product analysis.
- Standard Operating Procedures (SOPs): Documentation of step-by-step processes for production, cleaning, equipment maintenance, and personnel responsibilities.
- Deviation and Complaint Handling: Basic recording of deviations, complaints, and corrective measures.

While Schedule M provides robust guidance for traditional documentation, it is primarily oriented toward paper-based systems and does not fully address modern challenges such as electronic records, computerized quality systems, and sophisticated audit trail requirements.

2.2 WHO-GMP and ALCOA+ Principles

WHO-GMP expands upon traditional documentation requirements by emphasizing data integrity, traceability, and electronic system governance. Central to this is the ALCOA+ framework, which ensures that all data generated during manufacturing, testing, and quality assurance is:

- Attributable: Each record clearly identifies the person performing the task.
- Legible: Data is readable and understandable for future reference.
- Contemporaneous: Recorded at the time the activity occurs.
- Original: Original or verified true copy of the record is maintained.
- Accurate: Data correctly reflects the actual activity or observation.
- Complete: All necessary information, including omissions, is documented.
- Consistent: Records follow standardized formats and procedures.
- Enduring: Data is preserved over time for future reference.
- Available: Records can be retrieved readily during inspections or audits.

WHO-GMP also explicitly addresses electronic record systems**, including:**

- Audit Trails: Automatic logging of changes to electronic records, capturing who made changes, when, and why.
- System Validation: Ensuring computerized systems are validated to produce reliable and reproducible data.
- Data Security: Protection against unauthorized access, modification, or deletion of data.
- Structured Deviation and CAPA Documentation: Formalized recording of deviations, investigations, root cause analysis, and corrective/preventive actions.

2.3 Practical Implications for Indian Manufacturers

The distinction between Schedule M and WHO-GMP documentation standards has significant practical implications, particularly for Indian manufacturers transitioning to digital quality systems:

1. **Regulatory Compliance Risks:**
   - Non-compliance with data integrity standards has been a common cause of regulatory actions. For example, Indian manufacturers have faced FDA warning letters or import bans due to missing electronic audit trails,

incomplete records, or inadequate CAPA documentation.

2. **Digital Transition Challenges:**
   - SMEs and legacy facilities often rely on paper-based systems, making it difficult to meet WHO-GMP expectations for computerized systems, traceability, and electronic batch records.
   - Training personnel in digital record-keeping and implementing validated electronic systems are critical steps for ensuring compliance.
3. **Enhanced Traceability:**
   - WHO-GMP's emphasis on traceability ensures that every action, measurement, and deviation can be linked back to a specific batch, operator, and timestamp, improving accountability and facilitating investigations in case of quality issues.
   - Schedule M requires batch documentation but does not fully standardize traceability in electronic environments.
4. **Quality Culture and Continuous Improvement:**
   - Comprehensive documentation under WHO-GMP reinforces a culture of accountability and quality awareness, as employees understand the significance of accurate record-keeping in risk management and regulatory compliance.
   - Proper data management enables meaningful trend analysis, process optimization, and proactive prevention of deviations, supporting continuous improvement initiatives.

2.4 Linking to Case Studies

- The toxic cough syrup incident (2022–2023) highlighted lapses in documentation and traceability among small-scale manufacturers, underscoring the consequences of weak adherence to both Schedule M and WHO-GMP standards.
- US FDA warning letters frequently cite data integrity and electronic record deficiencies, demonstrating that compliance with Schedule M alone is insufficient for international regulatory expectations.
- Large-scale Indian manufacturers that have adopted electronic batch records (EBR) and Laboratory Information Management Systems (LIMS) illustrate the feasibility and benefits of WHO-GMP-aligned documentation systems, improving audit readiness and quality assurance.

3. Personnel Competence and Ongoing Training

Human resources are a cornerstone of pharmaceutical manufacturing. Both India's Schedule M and WHO-GMP frameworks recognize that well-trained, competent personnel are essential for maintaining product quality, safety, and regulatory compliance. However, the two approaches differ in scope, depth, and emphasis regarding personnel competency and continuous professional development.

3.1 Schedule M Requirements for Personnel

Schedule M primarily focuses on minimum qualification standards and basic training:

- Qualification: Production, quality control, and supervisory staff must meet defined educational and professional qualifications.
- Training: Personnel must receive training in standard operating procedures (SOPs), hygiene, equipment handling, and basic GMP compliance.
- Responsibilities: Staff roles and responsibilities should be clearly assigned to ensure accountability in production and quality control operations.

This prescriptive framework ensures that minimum competency standards are met and provides regulators with clear criteria during inspections. However, it tends to be static, emphasizing initial training and compliance with existing procedures rather than fostering ongoing professional development or adaptability to new technologies.

3.2 WHO-GMP Emphasis on Continuous Education and Competency

WHO-GMP expands upon the prescriptive requirements of Schedule M by emphasizing continuous learning, documented competencies, and embedded quality culture:

- Continuous Professional Development (CPD): WHO-GMP requires that all personnel, including production operators, QC staff, and quality assurance professionals, engage in regular training programs that are updated to reflect new technologies, processes, and regulatory changes.
- Documented Competency: Training programs are systematically documented, with assessments to confirm comprehension and practical ability. This includes competency matrices linking personnel skills to job responsibilities.
- Roles and Responsibilities: WHO-GMP emphasizes clearly articulated and functional

roles, ensuring that accountability, decision-making authority, and oversight responsibilities are explicitly defined and understood.

- Embedding Quality Culture: Beyond technical training, WHO-GMP promotes a quality mindset throughout the organization, where employees understand the importance of their actions in maintaining product quality and patient safety.

3.3 Practical Implications for SMEs and Large Manufacturers

1. **Challenges for Small- and Medium-Scale Enterprises (SMEs):**
   - SMEs often have limited training budgets, smaller QA/QC teams, and high staff turnover, which can result in gaps in understanding GMP principles.
   - Training deficiencies are frequently cited as root causes of compliance issues, such as inadequate documentation, improper handling of deviations, and insufficient process monitoring.
   - WHO-GMP encourages a structured, ongoing training program to address these gaps and improve operational consistency.
2. **Benefits for Large Manufacturers:**
   - Large-scale manufacturers implementing WHO-GMP invest in comprehensive training programs, including digital learning modules, on-the-job mentoring, and refresher courses.
   - Regular training on risk management, process validation, data integrity, and emerging quality standards ensures that personnel remain capable of handling complex manufacturing processes and sophisticated electronic systems.
   - Embedding a quality-focused culture helps reduce deviations, improve process consistency, and enhance audit readiness.

CONCLUSION:

The comparative analysis of India's Schedule M and WHO-GMP guidelines highlights both alignment and gaps in regulatory requirements for pharmaceutical manufacturing. While Schedule M provides a strong foundation for ensuring drug quality, it is largely prescriptive and focuses on traditional manufacturing practices, whereas WHO-GMP emphasizes a risk-based, process-oriented approach, with greater attention to data integrity, continuous improvement, and global harmonization. Key differences were observed in areas such as documentation standards, validation practices, quality oversight, and flexibility in adopting new technologies. Bridging these gaps is essential for Indian manufacturers aiming to compete in international markets and comply with stringent global quality standards. Harmonization efforts, regulatory updates, and enhanced training for personnel can help align domestic practices with WHO-GMP, thereby improving product quality, patient safety, and the overall credibility of India's pharmaceutical industry. This study underscores the need for proactive measures to integrate international best practices into national regulations, fostering both compliance and global competitiveness.

REFERENCES:

1. World Health Organization. (2013). *WHO good manufacturing practices for pharmaceutical products: Main principles (TRS 986, Annex 2).* WHO. World Health Organization
2. World Health Organization. (2010). *WHO good manufacturing practices for active pharmaceutical ingredients (TRS 957, Annex 2).* WHO. World Health Organization
3. World Health Organization. *Quality assurance of pharmaceuticals: A compendium of guidelines and related materials, Volume 2: Good manufacturing practices and inspection* (10th ed.). WHO. World Health Organization
4. World Health Organization. (2025). *GMP for excipients used in pharmaceutical products (TRS 1052, Annex 2).* WHO. World Health Organization
5. World Health Organization. *Health products policy and standards: Good manufacturing practices overview.* WHO. World Health Organization
6. "CDSCO Begins Online Registration for Securing Revised Schedule M Extension; Deadline: May 2025." *ETPharma.* ETPharma.com
7. *India extends GMP compliance deadline to December 2025* – India-Briefing. India Briefing
8. "Pharma units likely to face action for Schedule M violations: Experts." *Business Standard.* Business Standard
9. "DCGI confirms enforcement of revised Schedule M norms by January 1, 2026." *ETPharma.* ETPharma.com
10. "Form A Application for Extension of Compliance with Revised Schedule M." *Gazette of India (GSR 127(E)).* CDSCO